Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163992 | 0.83 | HPGD (0.56) | HPGDHSD11B1CTSBCTSSCTSK | |
| SCHEMBL1163991 | 0.83 | HPGD (0.56) | HPGDHSD11B1CTSBCTSSCTSK | |
| SCHEMBL16424491 | 0.80 | HPGD (0.52) | HPGDHSD11B1CTSBCTSSCTSK | |
| SCHEMBL699775 | 0.77 | HPGD (0.54) | HPGDHSD11B1CTSBCTSSCTSK | |
| SCHEMBL18485325 | 0.77 | HPGD (0.54) | HPGDHSD11B1CTSBCTSSCTSK | |
| SCHEMBL12520059 | 0.76 | HPGD (0.52) | HPGDHSD11B1CTSBCTSSCTSK | |
| SCHEMBL16433812 | 0.74 | SMN1; SMN2 (0.50) | HPGDHSD11B1CTSBCTSSCTSK | |
| SCHEMBL16424100 | 0.74 | SMN1; SMN2 (0.50) | HPGDHSD11B1CTSBCTSSCTSK | |
| SCHEMBL16424112 | 0.74 | SMN1; SMN2 (0.50) | HPGDHSD11B1CTSBCTSSCTSK | |
| SCHEMBL16423599 | 0.74 | SMN1; SMN2 (0.50) | HPGDHSD11B1CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212960-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212960-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| WO-2011018495-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212960-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER | BDNF, PSEN1, CHRNA5 | HPGD 1088/4885HSD11B1 1939/4885CTSB 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.